Department of Social and Preventive Medicine, State University of New York at Buffalo, 265 Farber Hall, Buffalo, NY 14214, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):239-42. doi: 10.1158/1055-9965.EPI-11-1012. Epub 2011 Nov 8.
While there is accumulating evidence that use of nonsteroidal anti-inflammatory drugs (NSAID) decreases breast cancer risk, little is known about the impact of NSAIDs on survival after breast cancer diagnosis.
We assessed whether recent, prediagnostic NSAID use and lifetime cumulative aspirin use before diagnosis were associated with survival among 1,024 women with incident, primary, invasive breast cancer.
Recent prediagnostic use of aspirin, ibuprofen, and acetaminophen and lifetime use of aspirin up to diagnosis were not associated with either all-cause mortality or breast cancer-specific mortality. Neither dose nor frequency of use was associated with risk. Associations were not different for pre- and postmenopausal women.
In our data, prediagnostic NSAID use and lifetime cumulative aspirin use were not associated with breast cancer survival.
Our findings do not support a role of NSAIDs prior to diagnosis in breast cancer survival.
虽然越来越多的证据表明使用非甾体抗炎药（NSAID）可以降低乳腺癌的风险，但对于 NSAID 对乳腺癌诊断后生存的影响知之甚少。
我们评估了最近的、诊断前的 NSAID 使用情况和诊断前终生累积使用阿司匹林与 1024 名患有原发性、浸润性乳腺癌的女性的生存情况之间的关系。
最近诊断前使用阿司匹林、布洛芬和对乙酰氨基酚以及诊断前终生使用阿司匹林与全因死亡率或乳腺癌特异性死亡率均无关。使用剂量和频率均与风险无关。在绝经前和绝经后妇女中，相关性没有差异。
在我们的数据中，诊断前 NSAID 的使用和终生累积使用阿司匹林与乳腺癌的生存无关。
我们的研究结果不支持 NSAID 在诊断前在乳腺癌生存中的作用。
